The OncLive Supportive Care condition center page is a comprehensive resource for clinical news and expert insights on supportive care and management of patients with cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, best practices, and ongoing research as it relates to supportive care for patients with cancer.
January 27th 2023
Despite American Society of Clinical Oncology guidelines calling for introduction of palliative care early in the course of disease, these services remain underused.
November 25th 2022
September 9th 2022
Investigators Navigate the Complicated Treatment Landscape of Chemotherapy-Induced NeutropeniaJanuary 19th 2022
Advances in the treatment of solid tumors and hematologic malignancies have resulted in the development of thera-peutic regimens that can be administered at various points in a patient’s care.
FDA Greenlights Maribavir for Select Post-Transplant Recipients With CMVNovember 24th 2021
The FDA has approved maribavir for the treatment of adult and pediatric patients aged 12 years and older weighing at least 35 kg who have post-transplant cytomegalovirus infection that does not respond to available antiviral treatment.
Roxadustat Shows Activity Against Chemotherapy-Induced Anemia in Non-Myeloid MalignanciesAugust 26th 2021
The first-in-class small molecule HIF-PHI inhibitor roxadustat demonstrated promising efficacy with favorable tolerability when used in the treatment of chemotherapy-induced anemia in patients with non-myeloid malignancies, meeting the primary end point of the phase 2 WHITNEY trial.
FDA Issues a Complete Response Letter for Eflapegrastim for Chemo-Induced NeutropeniaAugust 6th 2021
The FDA has issued a complete response letter to Spectrum Pharmaceuticals regarding the biologics license application for eflapegrastimas a potential option for the management of chemotherapy-induced neutropenia.
ACCC Tool Gives Individualized Guidance for Geriatric Assessment Implementation in Patients With CancerJune 2nd 2021
Melissa (Kah Poh) Loh, BMedSci, MBBCh, BAO, discusses the challenges of utilizing geriatric assessment in oncology and steps that the ACCC resources can provide to institutions that want to incorporate geriatric assessment into practice.
FDA Grants Priority Review to Maribavir for Select Post-Transplant Recipients With CMVMay 21st 2021
The FDA has accepted a new drug application for maribavir for the treatment of post-transplant recipients with cytomegalovirus infection who are refractory and/or resistant to previous anti-CMV treatment.
Plinabulin/Pegfilgrastim Combo Reduces Rate of Chemotherapy-Induced NeutropeniaNovember 16th 2020
November 16, 2020 - The combination of plinabulin and pegfilgrastim showed a statistically significant improvement in the rate of prevention of grade 4 neutropenia versus pegfilgrastim alone in patients with cancer undergoing chemotherapy.
Trilaciclib Reduces Need for G-CSF, RBC Transfusions From Chemo-Induced AEs in ES-SCLCOctober 19th 2020
Treatment with the CDK4/6 inhibitor trilaciclib prior to chemotherapy compared with placebo significantly reduced the need for supportive care interventions in the management of severe neutropenia and grade 3/4 anemia induced by chemotherapy in patients with extensive-stage small cell lung cancer.
Avatrombopag Falls Short in Chemotherapy-Induced ThrombocytopeniaOctober 9th 2020
Avatrombopag failed to meet the composite primary end point of avoiding platelet transfusions, chemotherapy dose reductions by 15% or greater, and chemotherapy dose delays by 4 days or more in patients with solid tumors and chemotherapy-induced thrombocytopenia.
Smith-Stanley Shares Strategies to Address Gender Disparities in OncologySeptember 30th 2020
To address disparities, it is important for institutions to embrace and promote the fostering of an inclusive culture and environment for healthcare professionals of all races and genders, and to adequately equip women specifically with the tools they need to achieve success in the field.
From the Ophthalmologist’s Eye: Managing Ocular Toxicities With Belantamab Mafodotin in MyelomaSeptember 25th 2020
Shaily Shah, MD, discusses disease and treatment-related ocular toxicities that can arise in patients with cancer, specific management strategies for patients receiving belantamab mafodotin who develop ocular toxicities, and the importance of collaborative management of these patients.
Managing Systemic Toxicities and Limiting Therapy Non-Adherence in Breast CancerJuly 31st 2020
One of the most important tasks that oncology nurses face is ensuring that patients are taking their medications consistently and correctly, and that adverse events are properly managed—specifically in those patients with breast cancer.
F-627 Shows Strong, Durable Benefit in Chemotherapy-Induced Neutropenia in Breast CancerJuly 9th 2020
Efbemalenograstim alpha (F-627) has demonstrated strong and lasting benefit when used as a treatment for chemotherapy-induced neutropenia in patients with breast cancer, meeting the primary and secondary end points of a phase 3 study.
ASCO 2020 Delivers Growing Insights on Supportive Care, Genetic Testing, and Symptom ManagementJune 30th 2020
Dawn L. Hershman, MD, MS, spotlights important data pertaining to cancer care delivery, prevention, symptom management, and survivorship that were presented at the 2020 ASCO Virtual Scientific Program.
FDA Launches Pilot Website Housing Publicly Available PRO Data From Cancer TrialsJune 24th 2020
The FDA has launched a new initiative called Project Patient Voice, which is a website that will serve as a source of publicly available information regarding patient-reported symptoms from cancer trials examining marketed treatments.
FDA Approves Burosumab-twza for Tumor-Induced OsteomalaciaJune 22nd 2020
The FDA has approved burosumab-twza (Crysvita) injection for the treatment of patients aged 2 and older with tumor-induced osteomalacia, which is described as the development of tumors that cause weakened and softened bones.
Plinabulin/Pegfilgrastim Combo Shows Efficacy in Prevention of Severe NeutropeniaJune 15th 2020
The combination of plinabulin and pegfilgrastim showed a significant enhancement in the rate of grade 4 neutropenia prevention compared with pegfilgrastim alone in patients undergoing chemotherapy, meeting the primary end point of a prespecified interim analysis of the phase 3 PROTECTIVE-2 trial.